President Trump approves a phase one trade agreement with China.

Joseph Corr

2020-01-01 13:39:00 Wed ET

President Trump approves a phase one trade agreement with China. This approval averts the introduction of new tariffs on Chinese imports. In return, China seeks to purchase $40 billion to $50 billion U.S. agribusiness exports to better balance the current Sino-American terms of trade. The Trump administration expects to phase out gradual tariff reductions for Chinese imports.

Meanwhile, the Trump administration reduces tariffs on $120 billion to $160 billion Chinese imports from 15% to 7.5%, but the separate 25% levies would remain on $250 billion Chinese imports. On the bright side, the current trade accord proves to be mutually beneficial to China and America, so the key U.S. and Chinese stock market indices surge in response to this great deal. The greenback depreciates a bit against a basket of U.S. fair-trade partners in response to the Sino-U.S. bilateral phase-one trade deal.

On the dark side, Chinese 5G technology now crystallizes as a clear challenger to the U.S. business model. A bifurcation of global supply chains has thus gone from a new niche to a mainstream consensus view. It is hence important for the Trump administration to strike a delicate balance between fair trade details and high-tech advances.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More
Carl Icahn mulls over steps to shake up the board of SandRidge Energy after it adopts a counter poison pill.
Jacob Miramar

2017-11-29 07:42:00 Wednesday ET

Carl Icahn mulls over steps to shake up the board of SandRidge Energy after it adopts a counter poison pill.

The octogenarian billionaire and activist investor Carl Icahn mulls over steps to shake up the board of SandRidge Energy after the oil-and-gas company adopt

+See More
It may be illegal for institutional investors to buy-and-hold large equity stakes in a less competitive industry with high market concentration.
Olivia London

2017-11-27 07:39:00 Monday ET

It may be illegal for institutional investors to buy-and-hold large equity stakes in a less competitive industry with high market concentration.

Is it anti-competitive and illegal for passive indexers and mutual funds to place large stock bets in specific industries with high market concentration? Ha

+See More
Mario Draghi declares the ECB agreement on a thorny set of revisions to Basel 3.
Rose Prince

2017-11-25 06:34:00 Saturday ET

Mario Draghi declares the ECB agreement on a thorny set of revisions to Basel 3.

Mario Draghi, President of the European Central Bank, heads the international committee of financial supervisors and has declared their landmark agreement o

+See More
Is Bitcoin a legitimate (crypto)currency or a new bubble waiting to implode?
Monica McNeil

2017-11-24 08:41:00 Friday ET

Is Bitcoin a legitimate (crypto)currency or a new bubble waiting to implode?

Is Bitcoin a legitimate (crypto)currency or a new bubble waiting to implode? As its prices skyrocket, bankers, pundits, and investors increasingly take side

+See More
Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin, Ethereum, and Ripple.
Becky Berkman

2017-11-23 10:42:00 Thursday ET

Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin, Ethereum, and Ripple.

As the TV host of Mad Money, Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin. First, no one knows the ano

+See More
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.
Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More